10x Genomics Market cap
What is the Market cap of 10x Genomics?
The Market cap of 10x Genomics, Inc. is $4.00B
What is the definition of Market cap?
Market capitalization is the market value at a point in time of the shares outstanding of a publicly traded company, being equal to the share price at that point of time times the number of shares outstanding.
= outstanding shares * previous day’s close
As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.
Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.
The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.
Market cap of companies in the Health Care sector on NASDAQ compared to 10x Genomics
What does 10x Genomics do?
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Companies with market cap similar to 10x Genomics
- Enstar has Market cap of $3.99B
- SCOR SE has Market cap of $3.99B
- William Hill Plc has Market cap of $3.99B
- Emmi AG has Market cap of $4.00B
- Independence Realty Trust Inc has Market cap of $4.00B
- Independence Realty Trust has Market cap of $4.00B
- 10x Genomics has Market cap of $4.00B
- Crescent Point has Market cap of $4.00B
- Turkcell Iletisim Hizmetleri A.S has Market cap of $4.00B
- Chegg Inc has Market cap of $4.00B
- MEG has Market cap of $4.01B
- Sinopec Shanghai Petrochemical has Market cap of $4.01B
- Jumia Tech. Sp.Adr/2 O.N has Market cap of $4.01B